A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder

Background Depression is a leading cause of psychiatric morbidity in the modern world, and the introduction of selective serotonin reuptake inhibitors (SSRIs) is a revolution in the treatment of depression. Vilazodone, a novel SSRI and 5-HT1A partial agonist, received FDA approval in 2011 to treat t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Shubhadeep, Chary, Sreenivasa, Thakur, Pankaj, Talluri, Leela, Reddy, Mohan, Verma, Kamal K, Saha, Pradeep, Gupta, Vijaya B, Ramaiah, Kaja A, Khanum, Siquafa Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Family/General Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412205/
https://www.ncbi.nlm.nih.gov/pubmed/34513348
http://dx.doi.org/10.7759/cureus.16689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412205/
https://www.ncbi.nlm.nih.gov/pubmed/34513348
http://dx.doi.org/10.7759/cureus.16689

Ejemplares similares